{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:25:13Z","timestamp":1787009113785,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Medical Science and Technology Development Project of Yancheng","award":["YK2021080"],"award-info":[{"award-number":["YK2021080"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Owing to the nonspecific symptoms in early stage and the propensity for secondary obstructive jaundice, cholangiocarcinoma (CCA) is frequently diagnosed at an advanced stage, thereby missing the optimal window for surgical intervention. The aim of this study was to evaluate the efficacy and safety of biliary stenting implantation with 125I seed strand (SI) plus chemotherapy with PD-1inhibitor for patients with CCA and malignant obstructive jaundice (MOJ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between January 2015 and December 2023, 88 patients diagnosed with CCA and MOJ were enrolled for this retrospective study. Then, 36 patients (observation group) received SI plus chemotherapy with PD-1inhibitor, whereas 52 patients (control group) received biliary stenting implantation plus chemotherapy. The response to therapy and adverse effect were compared between both groups. The data of stent patency time, progression-free survival (PFS) and overall survival (OS) obtained through clinical follow-up, were performed using the Kaplan\u2013Meier method and analysed with the log-rank test. Prognostic risk factors were evaluated using Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After the 6-month follow-up, the DCR (86.11% vs 67.31%) was statistically different (P\u00a0=\u00a00.045), while ORR (33.33% vs 23.08%) not (P\u00a0=\u00a00.288) between both groups. There were no serious interventional treatment-related adverse events and the differences of severe toxicities of chemotherapy between both groups were not statistically significant (P\u00a0&amp;gt;\u00a00.05). The median stent patency time, PFS and OS were 300\u00a0days (95%CI 260\u2013330) vs 215\u00a0days (95%CI 194\u2013240), 360\u00a0days (95%CI 260\u2013372) vs 230\u00a0days (95%CI 200\u2013248) and 420\u00a0days (95%CI 330\u2013452) vs 309\u00a0days (95%CI 252\u2013340) between both groups, respectively and the differences between both groups were statistically significant (P\u00a0&amp;lt;\u00a00.05). Staging of CCA and subsequent therapy method were independent risk factors that affected the prognosis for survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SI plus chemotherapy with PD-1inhibitor is an effective and safe therapy and shows promising results compared to biliary stenting implantation plus chemotherapy for CCA patients with MOJ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf123","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:28:56Z","timestamp":1753270136000},"page":"1237-1246","source":"Crossref","is-referenced-by-count":1,"title":["Biliary stenting implantation with 125I seed strand followed by chemotherapy plus PD-1 inhibitor in cholangiocarcinoma with malignant obstructive jaundice: a retrospective comparative study"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5714-0616","authenticated-orcid":false,"given":"Tianhua","family":"Yue","sequence":"first","affiliation":[{"name":"Department of Interventional Radiology, Yancheng First Hospital Affiliated of Nanjing University Medical College , Jiangsu, Yancheng 224000 ,","place":["China"]},{"name":"Department of Interventional Radiology, Jianhu County People's Hospital , Jiangsu, Jianhu 224700 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jianhu County People's Hospital , Jiangsu, Jianhu 224700, \u00a0","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, The Affiliated Cancer Hospital of Nanjing Medical University , Jiangsu, Nanjing 210000 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"2025110905435848200_ref1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025110905435848200_ref2","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.4240\/wjgs.v15.i7.1262","article-title":"Pathophysiological consequences and treatment strategy of obstructive jaundice","volume":"15","author":"Liu","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"2025110905435848200_ref3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025110905435848200_ref4","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025110905435848200_ref5","doi-asserted-by":"publisher","first-page":"e003214","DOI":"10.1136\/jitc-2021-003214","article-title":"Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes","volume":"9","author":"Chen","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025110905435848200_ref6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21037\/apm.2020.03.14","article-title":"Treatment of advanced intrahepatic cholangiocarcinoma with sintilimab combined with tegafur-gimeracil-oteracil potassium capsules (S-1): a case report","volume":"9","author":"Liu","year":"2020","journal-title":"Ann Palliat Med"},{"key":"2025110905435848200_ref7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MOG.0000000000000606","article-title":"Advances in the treatment of biliary tract cancers","volume":"36","author":"Junior","year":"2020","journal-title":"Curr Opin Gastroenterol"},{"key":"2025110905435848200_ref8","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","article-title":"The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines","volume":"28","author":"Fong","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2025110905435848200_ref9","doi-asserted-by":"publisher","first-page":"751391","DOI":"10.3389\/fonc.2021.751391","article-title":"Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label","volume":"11","author":"Zhang","year":"2021","journal-title":"Phase II Study Front Oncol"},{"key":"2025110905435848200_ref10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"2025110905435848200_ref11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3892\/ijo.2023.5585","article-title":"Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (review)","volume":"63","author":"Yang","year":"2023","journal-title":"Int J Oncol"},{"key":"2025110905435848200_ref12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1159\/000518104","article-title":"Immune checkpoint inhibitors: the emerging cornerstone in cholangiocarcinoma therapy?","volume":"10","author":"Guti\u00e9rrez-Larra\u00f1aga","year":"2021","journal-title":"Liver Cancer"},{"key":"2025110905435848200_ref13","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2217\/imt-2022-0288","article-title":"Immune checkpoint inhibitors in cholangiocarcinoma","volume":"15","author":"Beri","year":"2023","journal-title":"Immunotherapy."},{"key":"2025110905435848200_ref14","doi-asserted-by":"publisher","first-page":"7547","DOI":"10.1007\/s00432-023-04704-3","article-title":"Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular-cholangiocarcinoma","volume":"149","author":"Jang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025110905435848200_ref15","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ijc.34372","article-title":"Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"},{"key":"2025110905435848200_ref16","doi-asserted-by":"publisher","first-page":"1292319","DOI":"10.3389\/fonc.2024.1292319","article-title":"Treatment with palbociclib and tislelizumab for CDKN2A-mutated and PD-L1-positive advanced intrahepatic cholangiocarcinoma: a case report and literature review","volume":"14","author":"Liang","year":"2024","journal-title":"Front Oncol"},{"key":"2025110905435848200_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114000","article-title":"Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up(TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)","volume":"202","author":"Roth","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025110905435848200_ref18","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/liv.15699","article-title":"Immune checkpoint inhibitor for patients with advanced biliary tract cancer: a cost- effectiveness analysis","volume":"43","author":"Zhu","year":"2023","journal-title":"Liver Int"},{"key":"2025110905435848200_ref19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.21037\/hbsn-24-352","article-title":"The evolving landscape of biliary tract cancers: comparing French and US National Comprehensive Cancer Network guidelines","volume":"13","author":"Ozer","year":"2024","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025110905435848200_ref20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.32074\/1591-951X-252","article-title":"Cholangiocarcinoma","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"2025110905435848200_ref21","doi-asserted-by":"publisher","first-page":"1286771","DOI":"10.3389\/fimmu.2023.1286771","article-title":"Safety and efficacy of biliary stenting combined with iodine-125 seed strand followed by hepatic artery infusion chemotherapy plus lenvatinib with PD-1 inhibitor for the treatment of extrahepatic cholangiocarcinoma with malignant obstructive jaundice","volume":"14","author":"Lin","year":"2024","journal-title":"Front Immunol"},{"key":"2025110905435848200_ref22","doi-asserted-by":"publisher","first-page":"e0277272","DOI":"10.1371\/journal.pone.0277272","article-title":"Effectiveness of ultrasound-guided percutaneous transhepatic biliary drainage to reduce radiation exposure: a single-center experience","volume":"17","author":"Park","year":"2022","journal-title":"PloS One"},{"key":"2025110905435848200_ref23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.5152\/dir.2020.20143","article-title":"Managing occluded stents in biliary obstruction using radiofrequency ablation combined with 125I-strand brachytherapy","volume":"27","author":"Yao","year":"2021","journal-title":"Diagn Interv Radiol"},{"key":"2025110905435848200_ref24","doi-asserted-by":"publisher","first-page":"11348","DOI":"10.1038\/s41598-019-47791-4","article-title":"Biliary stenting alone versus biliary stenting combined with 125I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma","volume":"9","author":"Pang","year":"2019","journal-title":"Sci Rep"},{"key":"2025110905435848200_ref25","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.21037\/apm-22-676","article-title":"The efficacy and safety of biliary stenting alone versus stenting combined with iodine-125 seed strand implantation for the treatment of cholangiocarcinoma with malignant obstructive jaundice: a prospective, nonrandomized, controlled clinical study","volume":"11","author":"Luo","year":"2022","journal-title":"Ann Palliat Med"},{"key":"2025110905435848200_ref26","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.21037\/atm-21-6392","article-title":"Self-expandable metallic stent with 125I seed strand in malignant biliary obstruction: a self-made delivery system and novel implantation method","volume":"9","author":"An","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025110905435848200_ref27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.12998\/wjcc.v9.i4.801","article-title":"Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice","volume":"9","author":"Wang","year":"2021","journal-title":"World J Clin Cases"},{"key":"2025110905435848200_ref28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2025110905435848200_ref29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMcpc2027092","article-title":"Case 8-2021: a 34-year-old woman with cholangiocarcinoma","volume":"384","author":"Goyal","year":"2021","journal-title":"N Engl J Med"},{"key":"2025110905435848200_ref30","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41467-023-37030-w","article-title":"Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer","volume":"14","author":"Zeng","year":"2023","journal-title":"Nat Commun"},{"key":"2025110905435848200_ref31","doi-asserted-by":"publisher","first-page":"943066","DOI":"10.3389\/fimmu.2022.943066","article-title":"Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma","volume":"13","author":"Zeng","year":"2022","journal-title":"Fron Immunol"},{"key":"2025110905435848200_ref32","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.jhep.2023.09.006","article-title":"EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","author":"European Association for the study of the liver","year":"2023","journal-title":"J Hepatol"},{"key":"2025110905435848200_ref33","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"2025110905435848200_ref34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"2025110905435848200_ref35","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.clinthera.2020.05.018","article-title":"Clinical application of Iodine-125 seed brachytherapy combined with anti-PD-1 antibodies in the treatment of lung cancer","volume":"42","author":"Sui","year":"2020","journal-title":"Clin Ther"},{"key":"2025110905435848200_ref36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","article-title":"Anti-PD-1 antibody in combination with radiotherapy as frst-line therapy for unresectable intrahepatic cholangiocarcinoma","volume":"22","author":"Zhu","year":"2024","journal-title":"BMC Med"},{"key":"2025110905435848200_ref37","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/17474124.2021.1853527","article-title":"Recent advances of immunotherapy for biliary tract cancer","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025110905435848200_ref38","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2217\/imt-2022-0225","article-title":"Immune checkpoint inhibitors and combinations with other agents in cholangiocarcinoma","volume":"15","author":"Skouteris","year":"2023","journal-title":"Immunotherapy"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/11\/1237\/63829050\/hyaf123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/11\/1237\/63829050\/hyaf123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T10:44:03Z","timestamp":1762685043000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/11\/1237\/8210837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,7,23]]},"published-print":{"date-parts":[[2025,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf123","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,23]]}}}